Search Results for: G1 Therapeutics Announces Clinical Trial
Articles
February 27, 2019
Sarepta Therapeutics Announces Positive & Robust Expression & Biomarker Data February 27, 2019
Sarepta Therapeutics, Inc. recently announced positive results from three Limb-girdle muscular dystrophy (LGMD) Type 2E clinical trial participants who received...
February 22, 2019
BrainStorm Announces First Contracted US Clinical Site for Phase 2 Progressive MS Study February 22, 2019
BrainStorm Cell Therapeutics Inc. recently announced Cleveland Clinic as the first US clinical site contracted for a planned Phase 2...
February 21, 2019
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial February 21, 2019
ADC Therapeutics recently announced the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability,...
December 11, 2018
Y-mAbs Therapeutics Announces FDA Clearance of IND December 11, 2018
Y-mAbs Therapeutics, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a humanized bispecific GD2 antibody.
March 16, 2018
SELLAS Life Sciences Group Announces Notice of Allowance From US PTO for New Patent Covering Composition of Matter for WT-1 Peptides March 16, 2018
SELLAS Life Sciences Group, Inc. recently announced that the US PTO issued a Notice of Allowance for US Patent Application No. 14/760,997 related to certain Wilms Tumor 1 (WT1) peptides.
March 15, 2018
SELLAS Life Sciences Group Announces Notice of Allowance From US PTO for New Patent Covering Composition of Matter for WT-1 Peptides March 15, 2018
SELLAS Life Sciences Group, Inc. recently announced that the US PTO issued a Notice of Allowance for US Patent Application...
November 9, 2017
G1 Therapeutics Announces Publication in Cancer Discovery November 9, 2017
G1 Therapeutics, Inc. recently announced the publication CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation, is available online...
November 8, 2016
Kamada Announces Plan for Phase II/III Clinical Trial November 8, 2016
Kamada Ltd. recently announced the clinical plan for the initiation of a Phase II/III clinical trial in the United States...
December 16, 2014
Lightlake Therapeutics Announces Licensing Deal With Adapt Pharma Limited Subsidiary December 16, 2014
LONDON, Dec. 16, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its...
January 26, 2024
DRUG DEVELOPMENT - Using a Novel Deep Cyclic Inhibition Mechanism to Treat Broad Range of RAS-Mutant Cancers January 26, 2024
Ben Zeskind, PhD, addresses the question: rather than targeting individual RAS mutations and treating chronically, is it possible to achieve broad therapeutic activity in a way that focuses on malignant cells while minimizing damage to healthy cells?
September 3, 2012
9/5/2012 September 3, 2012
Genmab Signs Potential Billion Dollar Agreement Genmab recently announced a global license and development agreement for daratumumab (HuMax-CD38), a human...
June 25, 2012
6/27/2012 June 25, 2012
Hovione Reports Significant Sales Growth Hovione recently announced that the consolidated sales for the fiscal year ended March 2012 amounted...
